Aslan, which went public in May 2018, said its varlitinib, codenamed ASLAN001, failed in a pivotal study dubbed TreeTopp that evaluated the asset for biliary tract cancer. The multinational study evaluated 127 patients who failed first-line therapy. The median PFS was 2.83 months for varlitinib in combination with the chemotherapy drug capecitabine compared to 2.79 months for the control arm, Aslan said.